Established in 2015, Qyuns (2509.HK) is a biopharmaceutical company exclusively focused on biological therapies for autoimmune and allergic diseases. Leveraging an integrated layout of R&D, manufacturing, and commercial collaboration, we aim to fully unlock the commercial value of our pipeline products. Through the efficient development of a series of long-acting bispecific antibodies, we are working to further consolidate our leading position in the autoimmune field, thereby raising the treatment standard for autoimmune diseases.  

Guided by the philosophy of "Innovation for the Great Majority," we are committed to addressing challenges of drug accessibility and affordability in our focus areas. We have built a robust pipeline comprising one approved and marketed product, one under NDA review, and three in Phase III clinical trials. Additionally, three long-acting bispecific antibodies have successfully reached out-licensing agreements overseas. Our therapeutic areas span dermatology, rheumatology, respiratory, and gastroenterology, covering a range of autoimmune and allergic diseases, including psoriasis, atopic dermatitis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease. This broad portfolio solidifies our leadership in the field of autoimmune and allergic diseases in China.